BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33843426)

  • 1. Bushen Yijing Decoction (BSYJ) exerts an anti-systemic sclerosis effect via regulating MicroRNA-26a /FLI1 axis.
    Cheng Z; Zhang J; Deng W; Lin S; Li D; Zhu K; Qi Q
    Bioengineered; 2021 Dec; 12(1):1212-1225. PubMed ID: 33843426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
    Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sato S
    Arthritis Res Ther; 2014 Apr; 16(2):R86. PubMed ID: 24708674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fli1 Deficiency Induces CXCL6 Expression in Dermal Fibroblasts and Endothelial Cells, Contributing to the Development of Fibrosis and Vasculopathy in Systemic Sclerosis.
    Taniguchi T; Asano Y; Nakamura K; Yamashita T; Saigusa R; Ichimura Y; Takahashi T; Toyama T; Yoshizaki A; Sato S
    J Rheumatol; 2017 Aug; 44(8):1198-1205. PubMed ID: 28507181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis.
    Akamata K; Asano Y; Taniguchi T; Yamashita T; Saigusa R; Nakamura K; Noda S; Aozasa N; Toyama T; Takahashi T; Ichimura Y; Sumida H; Tada Y; Sugaya M; Kadono T; Sato S
    Rheumatology (Oxford); 2015 Jul; 54(7):1308-16. PubMed ID: 25539827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1.
    Bujor AM; Haines P; Padilla C; Christmann RB; Junie M; Sampaio-Barros PD; Lafyatis R; Trojanowska M
    Int J Mol Med; 2012 Dec; 30(6):1473-80. PubMed ID: 23041765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.
    Wang Y; Fan PS; Kahaleh B
    Arthritis Rheum; 2006 Jul; 54(7):2271-9. PubMed ID: 16802366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fli1 Downregulation in Scleroderma Myeloid Cells Has Profibrotic and Proinflammatory Effects.
    Bujor AM; El Adili F; Parvez A; Marden G; Trojanowska M
    Front Immunol; 2020; 11():800. PubMed ID: 32508810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of aquaporin-1 in dermal fibroblasts and dermal microvascular endothelial cells possibly contributes to skin fibrosis and edema in patients with systemic sclerosis.
    Yamashita T; Asano Y; Saigusa R; Taniguchi T; Nakamura K; Miura S; Toyama T; Takahashi T; Ichimura Y; Hirabayashi M; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
    J Dermatol Sci; 2019 Jan; 93(1):24-32. PubMed ID: 30270117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Sclerosis Dermal Fibroblasts Suppress Th1 Cytokine Production via Galectin-9 Overproduction due to Fli1 Deficiency.
    Saigusa R; Asano Y; Nakamura K; Hirabayashi M; Miura S; Yamashita T; Taniguchi T; Ichimura Y; Takahashi T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
    J Invest Dermatol; 2017 Sep; 137(9):1850-1859. PubMed ID: 28528914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progranulin overproduction due to constitutively activated c-Abl/PKC-δ/Fli1 pathway contributes to the resistance of dermal fibroblasts to the anti-fibrotic effect of tumor necrosis factor-α in localized scleroderma.
    Miyagawa T; Ichimura Y; Nakamura K; Hirabayashi M; Yamashita T; Saigusa R; Miura S; Takahashi T; Toyama T; Taniguchi T; Akamata K; Yoshizaki A; Sato S; Asano Y
    J Dermatol Sci; 2018 Nov; 92(2):207-214. PubMed ID: 30268392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis.
    Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
    Exp Dermatol; 2016 Apr; 25(4):287-92. PubMed ID: 26661692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fli1-haploinsufficient dermal fibroblasts promote skin-localized transdifferentiation of Th2-like regulatory T cells.
    Saigusa R; Asano Y; Taniguchi T; Hirabayashi M; Nakamura K; Miura S; Yamashita T; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Trojanowska M; Sato S
    Arthritis Res Ther; 2018 Feb; 20(1):23. PubMed ID: 29415756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis.
    Asano Y
    Int J Biochem Cell Biol; 2015 Oct; 67():86-91. PubMed ID: 26055516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.
    Noda S; Asano Y; Nishimura S; Taniguchi T; Fujiu K; Manabe I; Nakamura K; Yamashita T; Saigusa R; Akamata K; Takahashi T; Ichimura Y; Toyama T; Tsuruta D; Trojanowska M; Nagai R; Sato S
    Nat Commun; 2014 Dec; 5():5797. PubMed ID: 25504335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis.
    Noda S; Asano Y; Takahashi T; Akamata K; Aozasa N; Taniguchi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    Rheumatology (Oxford); 2013 May; 52(5):790-9. PubMed ID: 23287360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis.
    Taniguchi T; Miyagawa T; Toyama S; Yamashita T; Nakamura K; Saigusa R; Ichimura Y; Takahashi T; Toyama T; Yoshizaki A; Sato S; Asano Y
    Exp Dermatol; 2018 Sep; 27(9):1030-1037. PubMed ID: 29947047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.
    Asano Y; Bujor AM; Trojanowska M
    J Dermatol Sci; 2010 Sep; 59(3):153-62. PubMed ID: 20663647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -].
    Asano Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.
    Maurer B; Stanczyk J; Jüngel A; Akhmetshina A; Trenkmann M; Brock M; Kowal-Bielecka O; Gay RE; Michel BA; Distler JH; Gay S; Distler O
    Arthritis Rheum; 2010 Jun; 62(6):1733-43. PubMed ID: 20201077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis.
    Miyagawa T; Taniguchi T; Saigusa R; Fukayama M; Takahashi T; Yamashita T; Hirabayashi M; Miura S; Nakamura K; Yoshizaki A; Sato S; Asano Y
    Rheumatology (Oxford); 2020 Aug; 59(8):2005-2015. PubMed ID: 31782787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.